The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” the analysts said, citing its potential to rival blockbuster drugs like Sanofi and Regeneron’s dupilumab.

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to develop and sell a band of cancer drugs. Under the deal, Kymera could receive up to $750M,

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal,